

REMARKS

Currently Claims 1-55 are pending. Claims 8, 12, 15, 17-18, 21, 24, 30, 34, 36, 40-43, 46-47 and 50 have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependencies. Claim 55 has been canceled without prejudice.

The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed applications.

Applicant has attached an Abstract on a separate sheet of paper as required by US practice.

Applicant respectfully submits that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:



Alice P. Bradney
Agent for Applicants
Reg. No. 51,491

Date: May 3, 2006
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988